anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sialorrhea, or drooling, has been reported to be a significant problem in 10%to 37% of patients with cerebral palsy. Excessive drooling may cause skin maceration, increased the burden of caregiver, affect articulation of the patients, and increase the risk of aspiration and dehydration. Many options, including various therapies, medications, surgeries and radiation, have been proposed to treat drooling. Yet none of these is universally successful and many have potential complications. Nerve endings of the parasympathetic post-ganglionic neurons secret aceylcholine. Botulinum toxin should be able to inhibit salivary gland secretion by blocking the release of acetylcholine. Very limited case series had proved fair result of botulinum toxin injection to treat drooling. However, most of the subjects were adult patients with neurological disorders. The purpose of this study is to evaluate the effectiveness of botulinum toxin injection to treat drooling in children with cerebral palsy, and to find the most appropriate dosage, duration of effect and side effects.
The retrospective group will consist of 200 randomly selected medical records of patients who had colonoscopy procedures for a 6 month period prior to study implementation (between 10/1/2019 to 4/1/2020). The retrospective control group will have received the current standard of care including: IV fluids for management of intra-procedural hypotension as indicated/ordered by the physician, PO intake at 30-45 minutes, up to a chair at 60 minutes, and all procedure related complications will have been treated (e.g. PONV) per physician order as is the current standard of practice in the GI Lab recovery area.
The invention discloses a traditional Chinese medicine plaster used for treating uric acid nephropathy, and belongs to the field of traditional Chinese medicine. It is considered by most modern scholars that uric acid nephropathy is caused by insufficient anti-pathogenic energy, or spleen kidney qi deficiency, or liver and kidney deficiency, and adephagia on greasy and surfeit flavour, overstrain, and emotion internal injuries. The traditional Chinese medicine plaster is prepared via a conventional method via adding vinegar, baijiu, and water into acorus calamus l, root of perny germander, root of ficus simplicissima lour., geum japonicum, aralia elata(Miq.) seem, kadsura heteroclita root or stem, gnetum parvifolium (Warb.) C. Y. Cheng., desmodium caudatum root, herb of drooping clinacanthus, root and rhizome of divaricate gynura, and herba bidentis bipinnate herba bidentis pilosae. It is confirmed via clinical tests that total effective rate of the traditional Chinese medicine plaster is 90%, and curative effect is excellent.
In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
Duloxetine hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). The chemical name of duloxetine hydrochloride is (+)-(S)-N-methyl-γ-(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The molecular formula is C18H19NOS•HCl, which corresponds to a molecular weight of 333.88. The structural formula is:

Duloxetine hydrochloride, USP is a white to off-white powder, which is freely soluble in methanol, soluble in dichloromethane, and slightly soluble in water. The molecular formula of duloxetine free base is C18H19NOS and its molecular weight is 297.38.

Each DRIZALMA SPRINKLE (duloxetine delayed-release capsule) for oral administration contains enteric-coated pellets containing a total of 22.4 mg, 33.6 mg, 44.9 mg or 67.3 mg of duloxetine hydrochloride, equivalent to 20 mg, 30 mg, 40 mg or 60 mg of duloxetine free base, respectively. These enteric-coated pellets are designed to prevent degradation of the drug in the acidic environment of the stomach. Inactive ingredients of the pellets include ascorbic acid, hypromellose, hypromellose phthalate, polyethylene glycol, starch, sucrose, sugar spheres, talc, titanium dioxide, and triethyl citrate. The capsule shell ingredients for 20 mg strength are D&C Yellow 10, FD &C Blue 1, FD &C Red 40, gelatin, sodium lauryl sulfate and titanium dioxide. The capsule shell ingredients for 30 mg strength are FD &C Blue 1, FD &C Red 40 and FD &C Red 3 (present in cap), gelatin, sodium lauryl sulfate and titanium dioxide. The capsule shell ingredients for 40 mg strength are gelatin, sodium lauryl sulfate and titanium dioxide. The capsule shell ingredients for 60 mg strength are D&C Yellow 10 (present in body), FD &C Blue 1, FD &C Red 40, FD &C Red 3 (present in cap), gelatin, sodium lauryl sulfate and titanium dioxide.

The imprinting ink for 20 mg, 30 mg, 40 mg, and 60 mg strength capsules was made of ammonia solution, black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol and shellac.

DRIZALMA SPRINKLE does not comply with the USP dissolution test.
Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate XOLAIR therapy in a healthcare setting and closely observe patients for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of XOLAIR should be based on criteria to mitigate risk from anaphylaxis [see Dosage and Administration (2.6), Warnings and Precautions (5.1) and Adverse Reactions (6.1, 6.2)].
The sham group undergoes sessions with the same technical settings, designed to produce similar scalp sensations but without effective penetration of the electric field into the brain. Each session lasts for 40 minutes, with two sessions conducted daily - one in the morning and one in the afternoon. The intervention is spread over a 10-day period, with sessions taking place five days per week, totaling two weeks.
We directly compared the analgesic effects of "superficial" and 'deep" repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in patients with central neuropathic pain. Fifty-nine consecutive patients were randomly assigned to active or sham "superficial" (using a figure-of-8 [F8]-coil) or "deep" (using a Hesed [H]-coil) stimulation according to a double-blind crossover design. Each treatment period consisted of 5 daily stimulation sessions and 2 follow-up visits at 1 and 3 weeks after the last stimulation session. The primary outcome was the comparison of the mean change in average pain intensity over the course of the treatment (group × time interaction). Secondary outcomes included neuropathic symptoms (NPSI), pain interference, patient global impression of change (PGIC), anxiety, depression, and catastrophizing. In total, 51 patients participated in at least one session of both treatments. There was a significant interaction between "treatment" and "time" (F = 2.7; P = 0.0024), indicating that both figure-8 (F8-coil) and H-coil active stimulation induced significantly higher analgesic effects than sham stimulation. The analgesic effects of both types of coils had a similar magnitude but were only moderately correlated ( r = 0.39, P = 0.02). The effects of F8-coil stimulation appeared earlier, whereas the effects of H-coil stimulation were delayed, but tended to last longer (up to 3 weeks) as regards to several secondary outcomes (PGIC and total NPSI score). In conclusion, "deep" and "superficial" rTMS induced analgesic effects of similar magnitude in patients with central pain, which may involve different mechanisms of action.
This research aims to determine whether HLA heterozygosity confers a protective effect against hepatitis B virus infection by analyzing the relationship between HLA diversity and the risk of hepatitis B virus (HBV) infection. A total of 327 hepatitis B patients were selected and categorized based on their clinical status: 284 patients with chronic HBV infection and 43 patients with HBV-related liver cirrhosis (LC). The control group included 304 healthy individuals. HLA genotyping for 11 loci, including HLA class I and class II, was conducted using next-generation sequencing. The results of this study indicate a statistically significant negative correlation between HLA class II heterozygosity and the risk of HBV infection. Specifically, heterozygosity in HLA-DQB1 (OR = 0.49, 95% CI = 0.31-0.76, p = 0.01277) and HLA-DRB1 (OR = 0.42, 95% CI = 0.24-0.77, p = 0.01855) were significantly associated with protection. Subgroup analysis was conducted to explore the effect of HLA diversity among pathological subtypes (chronic hepatitis B and control group, liver cirrhosis and control group). For liver cirrhosis, compared with the control group, a decreased risk of LC was possibly associated with the heterozygosity of HLA class I locus B (OR = 0.24, 95% CI = 0.09-0.65, p = 0.0591), but this hypothesis was not confirmed by other studies. The diversity of HLA, measured by HLA heterozygosity, was associated with a protective effect against HBV infection.
Participants will receive a placebo injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1 and at Week 24 in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
<P>PROBLEM TO BE SOLVED: To obtain a humectant for the skin having excellent durability of moisture retaining effect and sense of use and is highly safe.  <P>SOLUTION: The active ingredients of the humectant for the skin comprises a β-glucan-containing material and a thermally treated cell body of lactic acid bacterium. The β-glucan is preferably β-1,3-1,6-glucan. The humectant for the skin comprises 1-40 mass% calculated as β-glucan of theβ-glucan-containing material and 4-95 mass% of the thermally treated cell body of lactic acid bacterium in the solid content. The β-glucan-containing material is preferably prepared from at least one kind selected from a bacterium belonging to the genus Aureobasidium, a fruit body of a basidiomycete and a mycelium of a basidiomycete. The β-glucan-containing material is preferably a culture obtained by culturing Aureobasidium pullulans M-1(FERM P-19213). The lactic acid bacterium is preferably Enterococcus faecalis.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Extended release prepns. to prevent or rectify salt deficiency conditions arising from extensive sweating in hard physical work or sporting exertions contain the most important cations in the approximate proportions found in sweat: sodium ion 78-92 wt.%, potassium ion 5-15 wt.%, calcium ion 2.5-5.0 wt.%, magnesium ion 0.5-2.0 wt.%. - The prepns. are in the form of tablets, conventional dragees or film dragees, or granulates. Apart from the usual carriers and additives the prepns. contain 15-20 wt.% sodium-carboxy-methyl -amylo-pectin to provide the extended release effect over 3-4 hours.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to gastroenterology, and concerns treatments of the patients with hyperbilirubinemia. That is ensured by conventional pharmacotherapy combined with oral introduction of hepabene in a dose 1 capsule 3 times a day at mealtimes from the first day of treatment. From the next day, intravenous introductions of ozonised physiologic saline of table salt in volume 200 ml with ozone concentration 500 mcg/ml and introduction rate 8-10 ml/min is applied. The course includes 6 infusions every second day. After that preparation Hepabene is continued in a dose 1 capsule twice a day at mealtimes during 7-10 days. ^ EFFECT: method provides effective decrease in bilirubin with reduced treatment time. ^ 2 ex
A method for minimizing microbial contamination of contact lenses during the handling of the lenses. The method comprises instructing a person that wears contact lenses to wash their hands prior to the handling of the contact lenses with a wash composition. The wash composition includes one or more surfactants selected from the group consisting of non-ionic, cationic, amphoteric or zwitterionic surfactants, and optionally, an anionic surfactant. The wash composition also includes an antimicrobial agent that is compatible with ocular tissue. The invention is also directed to a kit for to assist contact lens wearers with the care maintenance of their lenses. The kit includes the wash composition and a multipurpose contact lens solution. The wash composition is suitable for use with the multipurpose contact lens solution.
PURPOSE:To obtain an anti-cancer medicine composition of amorphous benzoylurea compound having excellent water solubility and absorption from digestive tubes, comprising a benzoylurea compound and a water-soluble polymer compound. CONSTITUTION:A benzoylurea compound of the formula (X is halogen or nitro; Y is Y, halogen, nitro, methyl, ethyl or trifluoromethyl; Z1 is halogen or trifluoromethyl; Z2 is H or halogen; A is CH or N) and a water-soluble polymer compound (e.g. hydroxypropylmethyl cellulose phthalate) are dissolved in a solvent (e.g. acetone) to give a solution, from which the solvent is removed to give a medicine composition. 0.5-15 pts.wt. water-soluble polymer compound and 30-200 pts.wt. solvent are used based on 1 pt.wt. compound of the formula. The medicine composition can suppress harmful reaction and disorder caused by administration in a large amount.
This study is an international, multi-center, non-comparative, phase IIIb, treatment optimization study of daily 80 mg asciminib (as either as 40 mg BID of asciminib or as 80 mg QD) in adult patients previously treated with 2 or more TKIs. Up to 30 patients who are intolerant to ongoing TKI treatment but in major molecular response (MMR) will also be allowed to enter the trial. Enrollment will be used to have a balance in the allocation of treatment into either asciminib 40 mg b.i.d. or 80 mg q.d. Although this trial will not be powered to compare both treatments, descriptive data from both treatment groups is expected to provide additional insight into the optimal patient management In patients not achieving MMR at 48 weeks or losing the response after the week 48 up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation. In addition, there must not be any grade 3 or 4 toxicity while on therapy, or persistent grade 2 toxicity, possibly related to asciminib and unresponsive to optimal management.

The planned duration of treatment is up to 144 weeks unless patient discontinue from treatment due to unacceptable toxicity, disease progression and/or if treatment is discontinued at the discretion of the investigator or the participant prior to week 144.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: method involves their conversion to amorphous state. The first variant of method involves thermal treatment or mechanical-chemical treatment of medicinal substance in mixture with agent inducing conversion to amorphous state and agent stabilizing amorphous state. Thermal treatment is carried out at temperature below the initiation point to amorphous state. This temperature is observed at measurement of temperature rate increase 10 C/min by differential scanning calorimeter. At temperature of treatment medicinal substance must not to be decomposed. The second variant of method involves high-frequency thermal treatment of moderately water-soluble medicinal substance and agent stabilizing amorphous state. Treatment temperature is taken under conditions that are similar to the first variant. Invention claims pharmaceutical composition that is solid dispersion of moderately water-soluble medicinal substance obtained by one of method claimed. Invention ensures to design preparations of moderately water-soluble medicinal substances with enhanced absorption of these substances. EFFECT: enhanced effectiveness and safety of preparations effect. 7 cl, 11 ex
Stiff elbow is a complex condition whose diagnosis and management are sometimes quite a challenge. Compared to the other joints, the elbow is disproportionately affected by loss of motion following trauma or surgery. It is unclear why the elbow tends to develop stiffness; its anatomical complexity, namely the presence of three highly congruent joints in the same capsule and synovial space, the tautness of the lateral and medial collateral ligaments through the whole range of motion, and the very close relationship among tendons, muscles, and skin 2 may account for this characteristic. In a stiff elbow, it is critical to assess the possible involvement of articular and periarticular tissues, particularly the degree of preservation of the articular surfaces and joint congruency. Morrey et al have classified post-traumatic stiff elbow into three types: 1) extrinsic contracture, which involves the soft tissue around the joint (capsule, ligaments, muscles) and heterotopic ossification across the joint, 2) intrinsic contracture, secondary to intra-articular fractures that have altered the anatomy of the articular surface, and 3) mixed contracture, combining intrinsic and extrinsic contracture. In the preoperative clinical assessment, we assume capsule contracture to be present in all patients with a stiff elbow. Two main associated lesions can affect prognosis and surgical management: heterotopic ossification and an altered bone joint anatomy. According to Morrey et al, most activities of daily living can be accomplished within an arc of motion from 30° to 130° in extension and flexion and of 50° in pronation and supination. The elbow arc of motion is not compensated for by the wrist and shoulder, thus loss of extension impairs the use of the hand in the space around the body and loss of flexion limits its use for grooming and self-care. The elbow should carefully be tested for deformity of the axial bone alignment (varus and valgus deformity) and rotational stability. Several treatment options are available for stiff elbow, from conservative management with a dedicated rehabilitation program to surgical treatment and from arthroscopic capsulectomy to joint replacement.
Abdominal visceral artery aneurysms (VAAs) are defined as aneurysms which involve branches of the celiac, superior mesenteric, inferior mesenteric or renal arteries. Owing to the improvements in imaging technology and the use of cross-sectional imaging modalities (ultrasound, computed tomography \[CT\], and magnetic resonance imaging), there is increase in the frequency of VAAs diagnosis. Although classically treated by open surgery, modern treatment strategies generally place interventional radiology techniques at the top of the treatment algorithm. Therefore, vascular interventional radiologists must become familiar with the indications for the treatment of VAA, become experienced in the different techniques, and know when to recommend treatment of VAA by interventional radiology techniques or to advocate open surgical repair.

VAAs are subdivided into true and false aneurysms. A true aneurysm involves all three layers of the arterial wall. Classically, a true aneurysm is defined as a localized dilatation of the artery by more than 1.5 times the expected arterial diameter. True aneurysms occur as a result of underlying arterial pathology such as atherosclerosis, fibromuscular dysplasia, and arteritis. The prevalence of true VAAs is 0.1-2%, and most true VAAs are asymptomatic. A minority may cause abdominal pain, which may be a harbinger of imminent rupture. VAAs are almost never large enough to be palpable by examination. False aneurysms, or pseudoaneurysms, are effectively contained ruptures of the artery that are lined by adventitia or by the perivascular tissues. False aneurysms may occur as a result of inflammation, infection, or trauma.
Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
Treating or preventing degeneration or destruction of articular cartilage and/or subchondral bone in the affected joint of a mammal is accomplished by administering a compound of Formula (I):      Formel 1 wherein the variables have the meanings given in the present description.      A preferred compound of formula (I) is   This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration. Whether or not a mammal needs such treatment is determined by whether or not it exhibits a statistically significant deviation from normal standard values in synovial fluid or membrane from the affected joint, with respect to at least five of the following substances: increased interleukin-1 beta (IL-1.beta.); increased tumor necrosis factor alpha (TNF.alpha.); increased ratio of IL-1.beta. to IL-1 receptor antagonist protein (IL-1Ra); increased expression of p55 TNF  receptors (p55 TNF-R); increased interleukin-6 (IL-6); increased leukemia inhibitory factor (LIF); decreased insulin-like growth factor-1 (IGF-1); decreased transforming growth factor beta (TGF.beta.); decreased platelet-derived growth factor (PDGF); decreased basic fibroblast growth factor (b-FGF); increased keratan sulfate; increased stromelysin; increased ratio of stromelysin to tissue inhibitor of metalloproteases (TIMP);  increased osteocalcin; increased alkaline phosphatase; increased cAMP responsive to hormone challenge: increased urokinase plasminogen activator (uPA); increased cartilage oligomeric matrix protein; and increased collagenase.